Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study

• Published in: Expert review of pharmacoeconomics & outcomes research Vol. 15; no. 4; p. 579
• Main Authors: Carrato, Alfredo, García, Pilar, López, Rafael, Macarulla, Teresa, Rivera, Fernando, Sastre, Javier, Gostkorzewicz, Joana, Benedit, Patricia, Pérez-Alcántara, Ferran
• Format: Journal Article
• Language: English
• Published: England 2015
• Subjects: Albumins - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - economics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cost-Benefit Analysis; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel - administration & dosage; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - economics; Pancreatic Neoplasms - pathology; Quality-Adjusted Life Years; Spain; Spain; nab-paclitaxel; pancreatic; cancer; cost; Spain
• ISSN: 1744-8379
• DOI: 10.1586/14737167.2015.1047349

The PANCOSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine (GEM) versus GEM alone in the treatment of patients with metastatic pancreatic cancer in Spain. Efficacy data were obtained from the MPACT study and were modeled to a lifetime horizon using a Markov model. The analysis was performed from the payer's perspective. Use of resources and key assumptions of the analysis were validated by a panel of oncologists. The addition of nab-paclitaxel to GEM showed higher effectiveness results (0.156 additional quality adjusted life years) at a higher cost (€6,477), resulting in a cost per quality-adjusted life years gained of €41,519. The combination of nab-paclitaxel and GEM has been shown to be an effective and well-tolerated option for the treatment of metastatic pancreatic cancer and, in addition to becoming the new standard of care, could also be considered a cost-effective option.